{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+hydrochloride+%28DOXIL%2FCAELYX%29", "query": { "intervention": "Doxorubicin hydrochloride (DOXIL/CAELYX)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1373, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Doxorubicin+hydrochloride+%28DOXIL%2FCAELYX%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-10T05:12:20.076Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00992030", "title": "R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Involved field irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Fondazione Michelangelo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2009-09", "completion_date": "2019-03", "has_results": false, "last_update_posted_date": "2021-08-19", "last_synced_at": "2026-10-10T05:12:20.076Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00992030" }, { "nct_id": "NCT05949021", "title": "OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "Combination of liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mridula George, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 30, "start_date": "2023-10-07", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-10-10T05:12:20.076Z", "location_count": 8, "location_summary": "Elizabeth, New Jersey • Jersey City, New Jersey • Lakewood, New Jersey + 3 more", "locations": [ { "city": "Elizabeth", "state": "New Jersey" }, { "city": "Jersey City", "state": "New Jersey" }, { "city": "Lakewood", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05949021" }, { "nct_id": "NCT00390793", "title": "Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "BCR-ABL1 Fusion Protein Expression", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Philadelphia Chromosome Positive", "Recurrent Acute Lymphoblastic Leukemia", "t(9;22)" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2006-09-28", "completion_date": "2024-02-02", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-10-10T05:12:20.076Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00390793" }, { "nct_id": "NCT06966700", "title": "A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Triple Negative Breast Neoplasms", "HR Low-Positive/HER2-Negative Breast Neoplasms" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2400, "start_date": "2025-06-30", "completion_date": "2034-12-29", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-10T05:12:20.076Z", "location_count": 63, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Clovis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06966700" }, { "nct_id": "NCT02192021", "title": "Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T Cell Lymphoma" ], "interventions": [ { "name": "Micro needle array-Doxorubicin (MNA-D)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Falo, Louis, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-03-09", "completion_date": "2020-12-09", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-10-10T05:12:20.076Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02192021" }, { "nct_id": "NCT07064018", "title": "Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Soft-tissue Sarcoma", "Triple Negative Breast Cancer", "Non-small Cell Lung Cancer", "Cervical Cancer", "Ovarian Cancer", "KRAS Mutation-Related Tumors" ], "interventions": [ { "name": "Spedox-6", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2025-04-30", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-10T05:12:20.076Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07064018" }, { "nct_id": "NCT00004048", "title": "Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "indium In 111 monoclonal antibody MN-14", "type": "RADIATION" }, { "name": "yttrium Y 90 monoclonal antibody MN-14", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 30, "start_date": "1998-09", "completion_date": "2002-05", "has_results": false, "last_update_posted_date": "2011-06-22", "last_synced_at": "2026-10-10T05:12:20.076Z", "location_count": 2, "location_summary": "Belleville, New Jersey • Paterson, New Jersey", "locations": [ { "city": "Belleville", "state": "New Jersey" }, { "city": "Paterson", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004048" }, { "nct_id": "NCT02229084", "title": "Vaccination of High Risk Breast Cancer Patients - A Combined Phase I/II Feasibility-and-Efficacy Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasms" ], "interventions": [ { "name": "P10s-PADRE/ MONTANIDE™ ISA 51 VG", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 58, "start_date": "2015-01-14", "completion_date": "2023-01-03", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-10T05:12:20.076Z", "location_count": 2, "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02229084" }, { "nct_id": "NCT05271318", "title": "Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Platinum-refractory Ovarian Carcinoma", "Platinum-resistant Ovarian Cancer", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin", "Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin", "Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin" ], "interventions": [ { "name": "TILT-123", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "pegylated liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TILT Biotherapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 29, "start_date": "2022-05-17", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-10T05:12:20.076Z", "location_count": 2, "location_summary": "Rochester, Minnesota • New York, New York", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05271318" }, { "nct_id": "NCT01906437", "title": "Cardiac Fibrosis by CMR in Patients With Cancer", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Cardiac Magnetic Resonance Scan", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-03", "completion_date": "2018-08-25", "has_results": false, "last_update_posted_date": "2018-09-14", "last_synced_at": "2026-10-10T05:12:20.076Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01906437" } ] }